Media ReleasesSUDA Pharmaceuticals

View All SUDA Pharmaceuticals News

SUDA Further Outlines Case For Share Consolidation And Appendix 3A.3

SUDA Pharmaceuticals Limited (ASX: SUD), a leader in oro-mucosal drug delivery, has attached its Appendix 3A.3: Notification of reorganisation of capital, being a proposed 1-for-25 share consolidation.

As announced on 14 October, the Directors consider that the share consolidation will result in a more appropriate and attractive capital structure for the company, not only for domestic Australian investors, but in particular US investors who are more cautious of “penny stocks” and companies with vast numbers of shares on issue.

For more information, download the attached PDF. 
Download this document